Patent application number | Description | Published |
20090054336 | Binding Agent - Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents. | 02-26-2009 |
20090221477 | Linkers - We disclose therapeutic polypeptides comprising at least two domains capable of binding to a cytokine receptor, wherein the domains are connected by a peptide linker, wherein the linker optionally comprises a rigid alpha helical region. | 09-03-2009 |
20090239801 | Modified Fusion Polypeptides - Chimeric polypeptides wherein the polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of such modified growth hormone binding domains. | 09-24-2009 |
20090270325 | GROWTH FACTOR - We describe a chimeric protein comprising a growth hormone polypeptide linked to a polypeptide comprising the extracellular binding domain of growth hormone receptor; its use in enhancing the growth and metabolism of non-human animals and homodimers comprising said chimeric protein. | 10-29-2009 |
20100035804 | POLYPEPTIDE ANTAGONIST - We describe a circularly permuted growth hormone polypeptide antagonist; compositions comprising said antagonist and methods to treat conditions that would benefit from administration of said antagonist. | 02-11-2010 |
20100136109 | SUSTAINED RELEASE - We describe a medicament for the treatment of thyroid disorders that typically result from a hypoactive thyroid gland that releases thyroxine and triiodothyronine in a sustained pattern when administered to a subject. | 06-03-2010 |
20100197582 | GROWTH HORMONE FUSION PROTEINS - We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said proteins. | 08-05-2010 |
20110008283 | INTERFERON FUSION PROTEINS - The disclosure relates to interferon fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers. | 01-13-2011 |
20110039775 | THYROID STIMULATING HORMONE FUSION PROTEINS - We disclose TSH fusion proteins comprising TSHα and/or TSH β and methods to treat diseases that would benefit from administration of TSH agonists and antagonists. | 02-17-2011 |
20110039814 | LIPID COMPOSITION - We describe lipid based pharmaceutical compositions adapted for oral delivery and optionally delivery in accordance with a circadian rhythm. | 02-17-2011 |
20110092417 | LEPTIN FUSION PROTEINS - The disclosure relates to leptin fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides. | 04-21-2011 |
20110152187 | INSULIN-LIKE GROWTH FACTOR FUSION PROTEINS - This disclosure relates to insulin-like growth factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides. | 06-23-2011 |
20110159095 | TREATMENT OF ADRENAL INSUFFICIENCY - The disclosure relates to a pharmaceutical formulation, for example a tablet, adapted for delayed and sustained release of hydrocortisone and a treatment regime that uses said tablet in the treatment of adrenal insufficiency. | 06-30-2011 |
20110182848 | GRANULOCYTE COLONY STIMULATING FACTOR - We disclose granulocyte colony stimulating factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said proteins. | 07-28-2011 |
20110230401 | INSULIN FUSION POLYPEPTIDES - We disclose insulin fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers. | 09-22-2011 |
20110245174 | GLP-1 FUSION POLYPEPTIDES - We describe nucleic acid molecules that encode fusion polypeptides comprising GLP-1, or a receptor binding part thereof, linked directly or indirectly to a polypeptide that naturally binds GLP-1. | 10-06-2011 |
20110275564 | ERYTHROPOIETIN - This disclosure relates to erythropoietin (EPO) fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides. | 11-10-2011 |
20130023477 | GROWTH HORMONE FUSION PROTEINS - We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers. | 01-24-2013 |
20140287052 | TREATMENT OF ADRENAL INSUFFICIENCY - The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to paediatric treatment regimens, the treatment of the elderly and non-human animals. | 09-25-2014 |
20140336117 | MODIFIED RECEPTOR FUSION PROTEINS - We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists. | 11-13-2014 |
20140370113 | HYDROCORTISONE CONTROLLED RELEASE FORMULATION - The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression. | 12-18-2014 |